No Settlement in Sight for Tandem Diabetes and Roche Patent Dispute

Published 1 hours agoTNDM

No Settlement in Sight for Tandem Diabetes and Roche Patent Dispute

Tandem Diabetes Care and Roche remain entangled in a patent dispute without a settlement in sight as of May 25, 2025. The legal battle centers around Roche's infringement claims that Tandem's t:slim X2 insulin pump violates their EP Patent No. 1 970 677 B1. Initially, Roche took the issue to the Unified Patent Court in Düsseldorf, Germany, in December 2023, demanding damages and halting Tandem's alleged infringement activities.

Supporting developments saw an April 2025 hearing at the UPC Düsseldorf, where Tandem countered with claims of non-infringement and argued for patent claim revocation. According to streetinsider.com, the court looked at both sides' arguments earlier this year, with a decision anticipated on May 22, 2025.

Despite these proceedings, there is no confirmation of an agreement or settlement between the companies. As the industry watches closely, statements from either company remain sparse, focusing more on addressing procedural aspects rather than any potential reconciliation or strategy-related announcements.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Tripadvisor Tackles Fake Reviews in 2024, Identifying 2.5 Million Fraudulent Entries

Tripadvisor Tackles Fake Reviews in 2024, Identifying 2.5 Million Fraudulent Entries

41 minutes agoTRIP

In 2024, Tripadvisor reported that about 8% of the 31.1 million reviews submitted on its platform were fake. This translates to roughly 2.5 million fraudulent reviews, highlighting a significant challenge for the company in maintaining the credibility of its vast review database. The issue of fake reviews is not new, but the scale revealed in this report is noteworthy. The company uses a layered moderation process that combines automated tools, human oversight, and community flagging to combat this problem. According to data, 87.8% of reviews passed initial automated checks, while 7.3% were blocked by technology, and 4.9% were flagged for further investigation. Reuters noted that different types of fake reviews include 'review boosting' from businesses, member fraud, vandalism, and paid reviews. To address these reviews, Tripadvisor has been proactive. The company removed 214,000 AI-generated reviews in 2024 to counteract misleading content. Approximately 9,000 businesses received warnings for engaging in unethical practices like incentivized reviews, reinforcing Tripadvisor's commitment to ensuring that users access genuine and reliable insights.

BioSig Technologies Shifts to Blockchain with Streamex Merger

BioSig Technologies Shifts to Blockchain with Streamex Merger

1 hours agoBSGM

BioSig Technologies, Inc. has announced plans to merge with Streamex Exchange Corporation, marking a significant shift from its traditional focus on medical technology to the burgeoning field of blockchain and digital asset tokenization. This move is underscored by a Letter of Intent (LOI) for an all-stock merger aimed at creating a publicly listed real-world asset (RWA) tokenization company on the Nasdaq, as noted on BioSig's official website. Following the transaction, Streamex's shareholders are expected to hold about 75% of the combined company's stock, while current BioSig stakeholders will retain the rest. Leadership changes are also on the horizon, with Henry McPhie, Co-Founder and CEO of Streamex, stepping in as the new CEO of the merged entity, and other key appointments lined up. This strategic realignment is supported by a team of strategic advisors who bring their expertise in commodities and U.S. capital markets. Despite the strategic rationale behind the merger, the market's response was initially negative, with BioSig's stock experiencing an 11.72% drop in pre-market trading on May 6, 2025, according to Ainvest. This reaction highlights investor uncertainty as BioSig navigates its new strategic direction, focusing on leveraging blockchain technology to enhance liquidity and efficiency in the commodity markets.

Nippon Steel Secures Approval for U.S. Steel Acquisition

Nippon Steel Secures Approval for U.S. Steel Acquisition

Nippon Steel Corporation has received the green light for its $15 billion acquisition of United States Steel Corporation after a notable endorsement from former President Donald Trump. This development signals a shift from Trump's previous stance against foreign acquisitions in the American steel industry during his 2024 campaign. Reuters reported that the political landscape has evolved through discussions involving key leaders, facilitating this favorable outcome for the partnership. The acquisition, projected to boost the U.S. economy by $14 billion within 14 months, is expected to create at least 70,000 new jobs, primarily benefiting Pennsylvania. Nippon Steel's increased investment commitment of $10.8 billion was pivotal in garnering political and union support despite ongoing concerns from the United Steelworkers union about the implications for domestic production and union jobs. Initially, the deal faced resistance from President Joe Biden and Vice President Kamala Harris due to national security concerns. However, after negotiations involving former President Trump and Japanese Prime Minister Shigeru Ishiba, the acquisition proceeded. Following the announcement, U.S. Steel's shares surged by 21%, marking their highest point since 2011, highlighting market optimism about the new partnership.

No Settlement in Sight for Tandem Diabetes and Roche Patent Dispute

No Settlement in Sight for Tandem Diabetes and Roche Patent Dispute

1 hours agoTNDM

Tandem Diabetes Care and Roche remain entangled in a patent dispute without a settlement in sight as of May 25, 2025. The legal battle centers around Roche's infringement claims that Tandem's t:slim X2 insulin pump violates their EP Patent No. 1 970 677 B1. Initially, Roche took the issue to the Unified Patent Court in Düsseldorf, Germany, in December 2023, demanding damages and halting Tandem's alleged infringement activities. Supporting developments saw an April 2025 hearing at the UPC Düsseldorf, where Tandem countered with claims of non-infringement and argued for patent claim revocation. According to streetinsider.com, the court looked at both sides' arguments earlier this year, with a decision anticipated on May 22, 2025. Despite these proceedings, there is no confirmation of an agreement or settlement between the companies. As the industry watches closely, statements from either company remain sparse, focusing more on addressing procedural aspects rather than any potential reconciliation or strategy-related announcements.